Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Pardubice – page 39

574 clinical trials in Pardubice, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Pardubice at a glance
574
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

574 trials in Pardubice

Open in trial search

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Erythema migrans+1

Not recruiting

Study on the Effects of Saccharomyces boulardii CNCM I-745 and Amoxicillin on Gut Health in Patients with Early Lyme Disease Undergoing Antibiotic Treatment

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Biocodex

Study on the Effects of Verekitug (UPB-101) for Patients with Chronic Rhinosinusitis with Nasal Polyps Using Nasal Corticosteroids

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Upstream Bio Inc.

Follicular lymphoma

Not recruiting

Study of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Beigene Ltd.

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Pardubice

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development for preventable diseases, including studies of new chickenpox vaccines and advanced meningococcal vaccines for infants and children.

  • Varicella immunization
  • Meningococcal disease prevention
  • Pediatric vaccine safety

Research emphasizes immune response monitoring and safety assessment in young populations.

02 Autoimmune Conditions

Innovative research targeting various autoimmune disorders, with studies evaluating new treatments for psoriatic arthritis and multiple sclerosis.

  • Plaque psoriasis treatments
  • MS therapy advancement
  • Immune system modulation

Trials focus on developing targeted therapies for chronic inflammatory conditions.

03 Neurological Disorders

Studies investigating new therapeutic approaches for Parkinson's Disease and other neurological conditions, with emphasis on improving patient outcomes.

  • Movement disorders
  • Neurodegenerative diseases
  • Symptom management

Research aims to enhance treatment options and quality of life for patients.

04 Oncology Research

Advanced clinical trials focusing on prostate cancer treatment, particularly addressing metastatic castration-resistant cases.

  • Targeted cancer therapies
  • Hormone-resistant cancers
  • Combination treatments

Studies emphasize novel therapeutic approaches for advanced-stage cancers.

05 Musculoskeletal Conditions

Research investigating treatments for osteoarthritis and joint disorders, including innovative therapies for knee-specific conditions.

  • Pain management
  • Joint function improvement
  • Inflammatory conditions

Focus on developing both systemic and topical treatments for joint diseases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.